Procedure Deep-Dive · November 20, 2026

Mast Cell Activation Syndrome, Mastocytosis, and Cosmetic Surgery: Anesthesia, Anaphylaxis, Tryptase, Premedication, Chronic Hives, Liposuction, and Breast Implants

Mast cell disorders range from a rare clonal bone marrow disease to one of the most overused labels on the internet, and both ends of that range matter to a cosmetic surgeon. True systemic mastocytosis raises the risk of anaphylaxis under anesthesia and changes the drug list, the operating room temperature, and the way skin gets scrubbed. Chronic hives and pressure urticaria turn compression garments and surgical tape into triggers. And self-diagnosed MCAS has become a common explanation for symptoms blamed on breast implants. Here is how to sort the real risk from the noise before surgery.

By The Editorial Desk

19 min read

A young woman with dark brown hair pulled into a loose low bun, wearing a heather-gray knit cardigan over a white t-shirt, seated at a light wooden table beside a large window, reading a sheet of paper, with two glasses of water, a notebook, and a pen on the table in front of her

She is 41 and booking a tummy tuck with liposuction of the flanks. On the intake form, under allergies, she has written "MCAS" and then, in the margin, a list that runs past the edge of the page: shellfish, red wine, fragrances, "most antibiotics," heat, stress. She takes cetirizine twice a day and famotidine at night. She has never had a bone marrow biopsy or a tryptase level drawn during a reaction. The diagnosis came from a telehealth visit and a symptom questionnaire. She is not sure whether she has ever had anaphylaxis, but she carries an epinephrine pen "just in case."

A second patient, a 56-year-old man asking about a breast reduction for gynecomastia, mentions small brown spots on his thighs and trunk that welt up and itch when he rubs them, and two episodes of fainting with flushing after bee stings. His primary care doctor checked a baseline tryptase last year because of low bone density and found it at 38 nanograms per milliliter. Nobody has explained what that number means.

The second patient is the one most likely to have a serious problem in the operating room, and he is the one who did not write anything on the allergy line. That inversion is the core difficulty with mast cell disorders in cosmetic surgery: the label is common, the confirmed disease is rare, and the patients at highest risk are not always the ones who arrive with the most paperwork.

What mast cell disorders are, and why the labels get confused

The short answer: mast cells are immune cells in skin, gut, airways, and around blood vessels that release histamine, tryptase, and other mediators, and the main disorders are systemic mastocytosis (a clonal disease with too many abnormal mast cells), mast cell activation syndrome (episodic, objectively documented mediator release across several organ systems), and chronic urticaria (hives lasting longer than six weeks), which are three different conditions with three different surgical implications.

Mast cells sit at the boundary between the body and the outside world. When they degranulate, they release histamine, tryptase, prostaglandin D2, leukotrienes, and dozens of other substances that cause flushing, itching, hives, swelling, wheezing, cramping, diarrhea, a racing heart, and a drop in blood pressure. In ordinary allergy, that release is triggered by IgE antibodies recognizing something specific, such as peanut or penicillin. In mast cell disorders, the cells release more easily, more often, or in greater number.

The conditions that get lumped together under "mast cell" are not interchangeable:

  • Cutaneous mastocytosis: mast cells accumulate in the skin alone. In adults it usually appears as small reddish-brown spots on the trunk and thighs, formerly called urticaria pigmentosa and now called maculopapular cutaneous mastocytosis. Rubbing a spot makes it swell and redden within minutes, a finding called Darier's sign. Most adults with these skin lesions turn out to have systemic disease when they are fully evaluated.
  • Systemic mastocytosis: a clonal disorder in which abnormal mast cells, driven in the large majority of adult cases by a KIT D816V mutation, accumulate in the bone marrow and sometimes in other organs. Indolent systemic mastocytosis is the most common form and is compatible with a normal lifespan. Advanced forms (aggressive systemic mastocytosis, mastocytosis with an associated blood cancer, and mast cell leukemia) are rare and serious. Diagnosis follows World Health Organization criteria and typically requires a bone marrow biopsy.
  • Mast cell activation syndrome (MCAS): episodes of symptoms in at least two organ systems at once, an objective rise in a mast cell mediator during an episode (the standard is a serum tryptase increase of 20 percent plus 2 nanograms per milliliter over the person's baseline, drawn within roughly one to four hours of symptom onset), and a response to mast cell directed medication. MCAS can be primary (clonal), secondary to another condition such as allergy, or idiopathic.
  • Chronic urticaria: hives, with or without deeper swelling called angioedema, that recur for more than six weeks. Chronic spontaneous urticaria affects somewhere around 1 percent of people at some point and is often autoimmune. Chronic inducible urticarias are provoked by a physical stimulus such as scratching, pressure, cold, heat, or sweating.
  • Hereditary alpha-tryptasemia: an inherited extra copy of the gene for alpha-tryptase, present in roughly 5 percent of people of European descent. It raises the baseline tryptase, usually into the 8 to 15 range, and in people who also have mastocytosis it is linked to more severe reactions.

The confusion arises because the symptoms overlap with everything. Flushing, fatigue, gut upset, brain fog, and food intolerance are common in the general population. The consensus criteria for MCAS, published by the European Competence Network on Mastocytosis and allergy specialists, were written precisely because the label was being applied without objective evidence. Reviews in the allergy literature have repeatedly warned that the label is overapplied, and specialist clinics describe many referred patients who do not meet the criteria and turn out to have other explanations, from gastrointestinal disease to anxiety to hereditary alpha-tryptasemia alone.

"The patients most likely to have a mast cell crisis under anesthesia often have the least on their allergy form. The patients with the longest lists often have a label nobody ever confirmed."

None of this means a patient with an unconfirmed MCAS label is imagining their symptoms. It means the surgical plan should follow the evidence. A confirmed systemic mastocytosis, a documented anaphylaxis history, and a high baseline tryptase all change the anesthetic plan. A label without objective data calls for a referral to an allergist or immunologist before elective surgery, not for an improvised list of forbidden drugs. Our piece on preoperative testing before cosmetic surgery makes the broader point: testing is useful when it answers a specific question, and here the question is whether the patient's mast cells are actually abnormal.

Anaphylaxis under anesthesia: who is actually at risk, and how the plan is built

The short answer: anaphylaxis during anesthesia occurs in roughly 1 in 10,000 anesthetics overall, and adults with systemic mastocytosis have a higher rate (published series put perioperative reactions in the range of about 2 percent of adults), with the risk concentrated in patients with prior anaphylaxis, high baseline tryptase, and advanced disease.

Perioperative anaphylaxis is uncommon but serious. The British national audit of anaphylaxis during anesthesia (NAP6), one of the largest studies of its kind, found the leading culprits to be antibiotics (teicoplanin and co-amoxiclav in the UK; in the United States, cefazolin is a frequent culprit), neuromuscular blocking drugs such as rocuronium and succinylcholine, chlorhexidine, and dyes. Latex was far less common than it once was. Our piece on penicillin allergy and drug allergies before cosmetic surgery covers how to sort true allergies from intolerances and why most penicillin labels do not survive testing.

For people with mastocytosis, the picture shifts. Two features stand out in the published data from Spanish and European mastocytosis networks:

  • The risk is real but smaller than the internet suggests. In a large Spanish series of patients with mastocytosis undergoing procedures with general or regional anesthesia, the rate of perioperative mast cell reactions in adults was about 2 percent, and severe reactions were less common still. Children with cutaneous mastocytosis had a somewhat higher rate. Most patients with mastocytosis have uneventful anesthetics when the team plans for them.
  • The risk is not evenly spread. Patients with a prior history of anaphylaxis, particularly to insect stings, those with very high baseline tryptase, those with advanced systemic disease, and those with extensive skin involvement carry more of it. A patient with indolent disease and no reaction history is in a very different category from a patient who has been resuscitated after a wasp sting.

The trigger in a mastocytosis patient is not always an allergen. Mast cells can be activated directly, without any antibody, by certain drugs that bind a receptor called MRGPRX2, and by physical stimuli: friction, pressure, temperature swings, and the mechanical trauma of surgery itself. That is why the surgical plan has to cover more than the drug list. It has to cover the room, the scrub, the warming blanket, and the cannula.

A related group that deserves mention is patients with severe reactions to bee, wasp, or yellow jacket stings. A meaningful share of adults with severe venom anaphylaxis, especially those whose reactions involve fainting without hives, turn out to have an underlying clonal mast cell disorder when tested. A history like the 56-year-old man's is a reason to check a baseline tryptase and refer before elective surgery.

The same caution applies to patients with other conditions that cluster with mast cell complaints, especially hypermobile Ehlers-Danlos syndrome and postural orthostatic tachycardia syndrome. Our pieces on Ehlers-Danlos syndrome and cosmetic surgery and POTS and dysautonomia before cosmetic surgery explain why these patients often need a coordinated plan across several specialists, and why the label alone does not tell you which risks apply.

Building the anesthetic plan. For patients with confirmed mastocytosis or documented MCAS, the plan usually includes a baseline tryptase before surgery, continuation of all daily mast cell medications, premedication with H1 and H2 antihistamines (sometimes with a leukotriene blocker or a corticosteroid for higher-risk patients), avoidance of drugs known to release histamine directly, a warm and calm environment, and epinephrine immediately available.

Guidance from the European Competence Network on Mastocytosis, the American Academy of Allergy, Asthma and Immunology, and anesthesia societies converges on a few principles. None of them are exotic, but each has to be written down, because the people who need to follow them on the day (the preoperative nurse, the anesthesiologist, the surgical technologist, the recovery room staff) may never have met the patient before.

Before surgery:

  • Get a baseline tryptase. It establishes a reference point. If a reaction happens during surgery, a tryptase drawn within one to two hours can be compared with it, which helps distinguish true mast cell activation from other causes of low blood pressure.
  • Do not stop daily medications. Long-acting antihistamines, montelukast, oral cromolyn, and omalizumab should continue. This is the opposite of the instruction patients get before allergy skin testing, and the two are often confused. Patients on midostaurin or avapritinib for systemic mastocytosis need their hematologist involved: these drugs affect blood counts, and avapritinib carries a warning about bleeding, including intracranial bleeding, particularly in advanced disease or with low platelets.
  • Review the medicines that make anaphylaxis harder to treat. Beta blockers blunt the response to epinephrine, and ACE inhibitors are associated with more severe reactions. Neither should be stopped casually, but the anesthesiologist needs to know.
  • Address anxiety. Emotional stress is a documented trigger for many patients, and a calm preoperative period is part of the treatment. Our piece on preoperative anxiety before cosmetic surgery describes what actually helps.

Premedication: many protocols give an H1 antihistamine (such as cetirizine or diphenhydramine) and an H2 blocker (such as famotidine) before induction, with a leukotriene blocker or a short corticosteroid course for patients with prior severe reactions. The evidence for premedication preventing anaphylaxis is limited, and specialists are candid that it may reduce milder reactions more than severe ones. It is a reasonable precaution, not a guarantee.

The drug list: the anesthesiologist should choose agents with the lowest tendency to trigger mast cells directly. The classic list of drugs to avoid or use with caution includes atracurium and mivacurium (neuromuscular blockers that release histamine), morphine, codeine, and meperidine (opioids with strong direct histamine release), and vancomycin given quickly. Fentanyl and its relatives, propofol, sevoflurane, and rocuronium or cisatracurium are generally used, though no drug is universally safe in every patient. Drugs the patient has previously tolerated without a reaction are valuable information and should be recorded. Our piece on anesthesia choice and the operative plan explains why general anesthesia, sedation, and regional blocks each carry different tradeoffs, and a mast cell disorder is one more variable in that choice.

Local anesthetics: true IgE-mediated allergy to amide local anesthetics such as lidocaine is rare. Most reactions attributed to "lidocaine allergy" are actually fainting, anxiety, or the racing heart caused by the epinephrine mixed with it. Lidocaine is used routinely in patients with mastocytosis. For tumescent liposuction, the dose limits discussed in our piece on lidocaine toxicity in tumescent liposuction still apply, and if a patient has a reaction history to a specific local anesthetic, allergy testing can clarify it before surgery.

Pain control afterward: NSAIDs are complicated in mast cell disease. They worsen hives in a substantial minority of people with chronic spontaneous urticaria and can trigger reactions in some patients with mastocytosis, while others take aspirin on purpose under specialist care to reduce prostaglandin-driven flushing. The answer depends on the patient's own history, not on a blanket rule. Our pieces on ibuprofen and NSAIDs after cosmetic surgery and opioid-sparing recovery describe the alternatives. Patients whose asthma flares with aspirin face a related issue, covered in our piece on asthma before cosmetic surgery.

The operating room and the recovery room: heat, friction, pressure, and garments

The short answer: physical stimuli activate mast cells directly, so patients with mastocytosis or inducible urticaria benefit from a warm but not hot room, warmed fluids, gentle skin preparation without vigorous scrubbing, careful padding at pressure points, minimal adhesive, and compression garments that are introduced and adjusted with their skin's response in mind.

This is where cosmetic surgery differs from most other operations. Body contouring involves a great deal of mechanical stimulation: large volumes of tumescent fluid, repeated cannula passes through fat and dermis, long operative times, extensive skin preparation, and weeks of compression afterward. Each of these is a plausible trigger for a patient whose mast cells respond to touch and temperature.

Temperature. Sudden cooling and sudden heating can both provoke mediator release. A cold operating room, cold skin prep solution, and room-temperature tumescent fluid infused in large volumes all drop skin temperature quickly. Most practices already warm patients to prevent hypothermia, and warmed tumescent fluid is common in larger liposuction cases. For a mast cell patient, it moves from good practice to a specific instruction. The opposite error also matters: overheated forced-air blankets and hot packs in recovery can provoke flushing and hives.

Friction. Vigorous scrubbing during skin preparation can raise wheals across the operative field in a patient with dermatographism or cutaneous mastocytosis. Painting the antiseptic on rather than scrubbing it in is a simple adjustment. Chlorhexidine itself is a recognized cause of perioperative anaphylaxis, independent of any mast cell disorder, and a patient with a reaction history should be asked about it specifically.

Liposuction trauma. The repeated mechanical action of a cannula is a form of controlled tissue injury. There is limited published data specific to liposuction in mastocytosis, so the reasonable approach is conservative: staged procedures rather than marathon combined cases, attention to total operative time, and avoidance of the largest-volume sessions in patients with prior severe reactions. Our piece on awake liposuction and what the evidence shows discusses when sedation-only approaches make sense, and for a mast cell patient the tradeoff includes fewer anesthetic drugs against the stress of being awake.

Adhesives and tape. Tape stripping is friction. Adhesive reactions are common in the general population and more likely in patients with sensitive skin, a topic our piece on adhesive and tape rash after cosmetic surgery covers in detail. Silicone-based tapes and dressings that release gently, and fewer of them, help.

Compression garments and delayed pressure urticaria. This is the problem most cosmetic practices do not anticipate. Delayed pressure urticaria is a form of chronic inducible urticaria in which deep, painful swelling appears four to eight hours after sustained pressure, under bra straps, waistbands, or shoulder bags. It often coexists with chronic spontaneous urticaria. A tight abdominal binder or a full-body liposuction garment is, from the skin's point of view, a sustained pressure stimulus over a large area. The resulting swelling can be mistaken for a seroma, a hematoma, or a garment that is simply too small. Symptomatic dermographism, the most common inducible urticaria, produces itchy linear welts wherever the garment's seams and edges rub.

None of this means these patients should skip compression. Our piece on compression garment evidence explains what garments do and do not accomplish, and the honest answer is that the evidence for strict, round-the-clock compression is weaker than most practices imply. That gives room to adapt: softer garments with flat seams, gradual tightening, a lined layer against the skin, regular skin checks, and a plan to loosen or change the garment if welts or deep swelling appear. Swelling that tracks the garment's pressure lines in a patient with known pressure urticaria is a different problem from a fluid collection, a distinction discussed in our pieces on seroma after plastic surgery and the normal swelling timeline after plastic surgery.

Itch during healing. Mast cells are recruited to every healing wound, and their histamine is one reason incisions itch during the second and third weeks. Our piece on itching after plastic surgery explains the normal biology. In patients with mast cell disorders, the itch can be more intense, and scratching can provoke hives along the incision. Continuing daily antihistamines through recovery, keeping the skin cool, and treating the itch early rather than late reduce the cycle.

Breast implants, fillers, lasers, and the MCAS explanation

The short answer: there is no good evidence that breast implants cause mast cell activation syndrome, and explantation should not be presented as a treatment for MCAS, while injectables and energy devices are usually possible in mast cell patients with test spots, conservative settings, and attention to heat and friction.

Online communities focused on breast implant illness frequently name MCAS as either the mechanism or a parallel diagnosis. The appeal is understandable: both involve diffuse, fluctuating, multisystem symptoms, and both offer a concrete explanation. But the published research does not support a causal link. Our piece on breast implant illness and what the science shows reviews the evidence on symptom improvement after explant, which is real for some patients but inconsistent, poorly controlled, and not tied to any identified immune mechanism. A patient who believes her implants caused MCAS deserves a proper evaluation, including a baseline tryptase, a tryptase drawn during an episode, and an allergist or immunologist who applies the consensus criteria. If she meets criteria, the condition is treated as MCAS. If she does not, the search for the cause of her symptoms continues, with or without explantation as a separate decision.

The reverse question also comes up: can a patient with confirmed mastocytosis have breast augmentation, a breast reduction, or a breast lift? Nothing in the guidance prohibits it. The considerations are the ones above, applied to a longer operation: anesthetic plan, temperature, friction, pressure from surgical bras, and a facility that can handle a reaction. For the 56-year-old man asking about gynecomastia, the real priority is completing the workup his tryptase level demands, which also includes a bone density follow-up, because osteoporosis and vertebral fractures are common in systemic mastocytosis, especially in men. Our piece on osteoporosis and cosmetic surgery covers how bone health affects surgical planning.

Fillers and neurotoxins. Botulinum toxin injections are generally well tolerated. Hyaluronic acid fillers involve needle trauma and can provoke local swelling, and in patients with dermatographism or cutaneous mastocytosis, wheals around injection points are common and usually short-lived. The more important distinction is between expected swelling and a different condition entirely. Recurrent episodes of lip or facial swelling without hives should raise the question of angioedema, including hereditary angioedema, which is a bradykinin disorder rather than a mast cell disorder and does not respond to antihistamines. Our piece on hereditary angioedema and cosmetic surgery explains why that distinction matters. Delayed lumps weeks after filler are a separate issue again, covered in our piece on delayed filler nodules.

Lasers, IPL, radiofrequency, and microneedling. Heat is a mast cell trigger, and so is the friction of rolling handpieces and microneedling devices. Treating directly over maculopapular cutaneous mastocytosis spots can produce intense local wheals and, rarely, systemic flushing. For patients who want vascular or pigment treatment, a test spot on a small area, cooling, lower energy, shorter sessions, and continuation of antihistamines are prudent. Flushing that comes with palpitations, diarrhea, or wheezing deserves a medical workup before anyone treats facial redness as a cosmetic problem, a point we make in our piece on facial redness and broken capillaries. Patients with eczema-prone skin face overlapping issues covered in our piece on eczema and cosmetic procedures.

Supplements and "mast cell diets." Many patients with MCAS labels take quercetin, high-dose vitamin C, or other supplements promoted for mast cell stabilization, and follow restrictive low-histamine diets. The evidence for most of these is thin. The surgical question is practical: some supplements affect bleeding or interact with anesthesia, and a restrictive diet before surgery can leave a patient short on protein and iron for healing. Our piece on supplements to stop before surgery lists the ones that matter.

When a reaction happens: recognition, epinephrine, and the tryptase clock

The short answer: a mast cell reaction during or after surgery usually shows up as low blood pressure, a fast heart rate, flushing or hives, wheezing, or swelling, it is treated first with epinephrine rather than antihistamines, and a serum tryptase should be drawn within one to two hours so the event can be confirmed and the cause investigated afterward.

Under general anesthesia, the classic early signs of anaphylaxis may be hidden. The patient cannot report itching or a sense of doom, drapes cover the skin, and the first clue may be a sudden fall in blood pressure, a rise in airway pressure, or a rapid heart rate. In recovery or at home, the signs are more familiar: flushing, hives, swelling of the lips or throat, abdominal cramping, vomiting, lightheadedness, or fainting.

The principles are consistent across allergy and anesthesia guidelines:

  • Epinephrine first. Antihistamines treat itching and hives. They do not reverse low blood pressure or airway narrowing. Delayed epinephrine is the most consistent feature of fatal anaphylaxis across studies. Patients with systemic mastocytosis and a prior anaphylaxis history are usually advised to carry two epinephrine auto-injectors, and they should bring them to the surgery center.
  • Lay the patient flat. Sudden standing or sitting upright during anaphylaxis can worsen low blood pressure dangerously.
  • Draw the tryptase. A serum tryptase drawn between about 30 minutes and 2 hours after the onset of symptoms, compared with the baseline, is the most useful single test for confirming mast cell activation. A practice that does not know how to draw and send this sample should find out before it treats a patient with a mast cell disorder.
  • Investigate afterward. A perioperative reaction should be followed by referral to an allergist, ideally within a few weeks, for testing of the drugs and agents involved. This protects the patient during any future surgery and avoids the common outcome in which a patient leaves with a vague label of "anesthesia allergy" that follows them for life.

Recovery-room events are easy to misread in the opposite direction, too. Nausea, flushing, and itching after opioids are common and usually not anaphylaxis, a subject covered in our piece on nausea after cosmetic surgery. Low blood pressure after body contouring is more often from fluid shifts or bleeding, discussed in our piece on anemia and blood loss before and after cosmetic surgery. Corticosteroids given for swelling can mask hives, as noted in our piece on steroids for swelling after plastic surgery. The tryptase level is what keeps everyone honest about which explanation is correct.

Patients with autoimmune conditions alongside chronic urticaria, which is common because chronic spontaneous urticaria is itself often autoimmune, may also be taking immunosuppressive drugs that affect healing. Our piece on cosmetic surgery with autoimmune disease covers that side of the plan. Omalizumab, the injectable anti-IgE antibody approved for chronic spontaneous urticaria since 2014 and widely used off-label in mastocytosis to reduce anaphylaxis, is generally continued around surgery, and the injection schedule can be arranged so that a dose falls a week or two before the operation.

The honest summary

Mast cell disorders occupy two very different places in cosmetic surgery. At one end is systemic mastocytosis, a confirmed clonal disease with a measurable increase in the risk of anaphylaxis under anesthesia, a known set of physical and drug triggers, and a well-established way to plan around them: baseline tryptase, continued daily medications, premedication, careful drug selection, a warm room, gentle skin preparation, conservative operative scope, and epinephrine within reach. Patients with indolent disease and no reaction history usually have uneventful operations when that plan exists. Patients with prior anaphylaxis, high tryptase, or advanced disease need their hematologist and an experienced anesthesiologist involved, and a hospital setting may be wiser than an office suite.

At the other end is a label, MCAS, that is often applied without the objective evidence the consensus criteria require. Those patients deserve to be taken seriously, which means sending them to an allergist or immunologist for a real evaluation, not adding twenty drugs to a forbidden list or promising that explanting their breast implants will resolve their symptoms. Chronic hives sit in between, and they bring a specific, underappreciated problem for body contouring: pressure and friction from garments and tape can provoke welts and deep swelling that look like surgical complications.

The patient who worries a cosmetic surgeon most is not the one with the longest allergy list. It is the one with unexplained flushing, brown spots that welt when rubbed, fainting after a sting, or a baseline tryptase nobody explained. If that sounds like you, get the diagnosis settled first. The surgery can wait for a few weeks. An unplanned reaction on the operating table is much harder to undo.